Scottish scientists have discovered how to control a major anti-tumour gene that could lead to more effective chemotherapy. According to a report in the
Cancer Cell Journal, research conducted by the Universities of St Andrews and Dundee may eventually lead to the development of new cancer drugs.
The gene, called p53 and known as "the guardian of the genome", is damaged or switched off in most cancers. But the resrchers found that they could reboot it using two new biological compounds called "tenovins".
In a laboratory study, the academics found that these compounds could kick-start p53 by turning off enzymes called sirtuins. Sirtuins act like genetic switches and keep p53 under control, ensuring that the cells stay alive.
Dr Nick Westwood from the School of Chemistry at the University of St Andrews said, "This is a great example of what can be done by researchers from different disciplines collaborating. This programme has successfully combined skills in cell and cancer biology, biochemistry, genetics and chemistry to deliver compounds of genuine therapeutic interest."
He explained, "The approach that we used to identify the tenovins differs from the main approach used today in many pharmaceutical and biotech companies. The compounds were initially selected for study because they induced the required effect on whole cells as opposed to the use of purified proteins.
"The research team then figured out the details of how the observed effect occurred. Whilst other examples of our experimental approach are known, it is quite an achievement to get this far. Our choice of approach has been justified as we have shown that both of the tenovins work in a cancer model."
Given that faults in p53 function contribute to many types of cancer, the discovery of less toxic chemicals that can restore or amplify its power has enormous potential.
Dr Sonia Lain from Dundee University and joint author of the study said, "Our findings indicate that improved tenovin derivatives may have the potential to stop tumours and that their ability to switch on p53 contributes to this.
"We have found that tenovins work by inhibiting sirtuins. This is important, as it may facilitate further optimisation of the compounds."
The research was jointly funded by Cancer Research UK, the University of Dundee and Tenovus Scotland, a charity which supports medical research in Scottish Universities.
Source: University of St Andrews
Related stories:
New cancer treatment targets both tumor cells and blood vessels
MU researchers develop nontoxic treatment that has broad anti-cancer potential
It takes more than one punch to fight tumors. Often, tumors have more than one way of surviving, and attacking the tumor alone is not enough. Now, in a new study, University of Missouri researchers have developed a new non-toxic treatment that effectively reduces breast cancer cells, by combining a small molecular drug that targets tumor cells with an antibody that causes selective shutdown of tumor blood vessels.
Researchers find roadmap to next-generation cancer therapies
Pinpointing new targets for cancer treatments is as difficult as finding a needle in a haystack, yet a University of Rochester team has discovered an entire novel class of genes they believe will lead to a greater understanding of cancer cell function and the next generation of effective and less harmful therapies for patients.
Ancient mechanism for coping with stresses also gives cancer a boost
An ancient mechanism for coping with environmental stresses, including heat and toxic exposures, also helps cancerous tumors survive, reveals a new report in the Sept. 21, 2007, issue of
Cell, a publication of Cell Press. The findings could lead to a new way to treat cancer and may also have implications for the treatment of neurodegenerative and other diseases, according to the researchers.
Reactivated gene shrinks tumors
Many cancers arise due to defects in genes that normally suppress tumor growth. Now, for the first time, MIT researchers have shown that re-activating one of those genes in mice can cause tumors to shrink or disappear.
Discovery of natural compounds that could slow blood vessel growth
Using computer models and live cell experiments, biomedical engineers at the Johns Hopkins University School of Medicine have discovered more than 100 human protein fragments that can slow or stop the growth of cells that make up new blood vessels.
New Organic Catalyst Should Improve Drug Development, Lower Costs
(PhysOrg.com) -- Chemists at Oregon State University have developed a new “organocatalyst” that will play a major role in new drug development, greatly reducing costs while making the process more efficient, effective and environmentally friendly.
Breast cancer cells recycle to escape death by hormonal therapy
Many breast cancer cells facing potentially lethal antiestrogen therapy recycle to survive, researchers say.
Cells that Avoid Suicide May Become Cancerous
(PhysOrg.com) -- When a cell's chromosomes lose their ends, the cell usually kills itself to stem the genetic damage. But University of Utah biologists discovered how those cells can evade suicide and start down the path to cancer.
